Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

摘要: Esophageal adenocarcinoma arises in the backdrop of Barrett metaplasia-dysplasia sequence, with vast majority patients presenting late-stage malignancy. Mesothelin, a glycophosphatidylinositol-anchored protein, is aberrantly overexpressed on surface many solid cancers. Mesothelin expression was assessed esophageal tissue microarrays encompassing entire histological spectrum Barrett-associated dysplasia and adenocarcinoma. observed 24/84 (29%) invasive adenocarcinomas 5/34 (15%) lymph node metastases. In contrast, normal squamous cardiac mucosa, as well noninvasive lesions, failed to label mesothelin. expressed cell line JH-EsoAd1 but not primary human epithelial cells. Anti-mesothelin antibody-conjugated CdSe/CDS/ZnS quantum rods were synthesized, confocal bioimaging confirmed robust binding nanoparticles can be useful for diagnosis therapy mesothelin-overexpressing adenocarcinomas.